ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Impact of Low Dose Donor Specific Anti-HLA Antibodies between Living Donor versus Deceased Donor Kidney Transplantation

S. Kim1, S. Lee1, E. Ko1, T. Ban2, J. Min3, H. Yoon4, C. Yang1, B. Chung1

1Internal Medicine, Seoul St. Mary's Hospital, Seoul, Korea, Republic of, 2Internal Medicine, Eunpyeong St. Mary's Hospital, Seoul, Korea, Republic of, 3Internal Medicine, Bucheon St. Mary's Hospital, Seoul, Korea, Republic of, 4Internal Medicine, Incheon St. Mary's Hospital, Seoul, Korea, Republic of

Meeting: 2020 American Transplant Congress

Abstract number: A-017

Keywords: HLA antibodies, Kidney transplantation, Rejection

Session Information

Session Name: Poster Session A: Kidney Acute Antibody Mediated Rejection

Session Type: Poster Session

Date: Saturday, May 30, 2020

Session Time: 3:15pm-4:00pm

 Presentation Time: 3:30pm-4:00pm

Location: Virtual

*Purpose: Presence of donor specific anti-HLA antibody (HLA-DSA) has significant impact on the short term and long term allograft outcomes after kidney transplantation. However, the impact of low dose HLA-DSA has not been fully investigated yet. The aim of this study is to investigate the impact of low dose HLA-DSA between living donor transplantation (LDKT) versus deceased donor kidney transplantation (DDKT).

*Methods: This study is a retrospective observational study. From January 2010 to December 2018, 627 living donor kidney transplant recipients and 364 deceased donor kidney transplant recipients at Seoul St. Mary’s Hospital were enrolled. The low dose HLA-DSA was defined as positive DSAs and negative crossmatch. The primary outcome was the development of biopsy proven acute antibody mediated rejection (BP-ABMR) and the secondary outcomes were change of allograft function, death-censored graft loss rate and patient mortality.

*Results: Of total 627 living donor kidney transplant recipients, 567 patients were negative HLA-DSA group and 60 patients were low dose HLA-DSA group. And total 364 deceased donor kidney transplant recipients, 355 patients were negative HLA-DSA group and 9 patients were low dose HLA-DSA group. In living donor kidney transplantation, acute antibody mediated rejection was increased in the low dose HLA-DSA group than in the negative HLA-DSA group significantly. In univariate analysis, the odds ratio of low dose HLA-DSA was 3.826 (1.695-8.636), and the odds ratios were 2.955 (1.071-8.147) and 6.550 (2.420-17.729) in positive HLA-DSA class I and positive HLA-DSA class II, respectively. In multivariate analysis, the odds ratio of positive HLA-DSA class II in the low dose HLA-DSA group was 8.179 (2.916-22.945) but positive HLA-DSA class I and positive total HLA-DSA were not stastically significant. In deceased donor kidney transplantation, acute antibody mediated rejection tended to increase in the low dose HLA-DSA group but was not statistically significant. Change of allograft function, death-censored graft loss rate and patient mortality were not significantly different between the low dose HLA-DSA group and the negative HLA-DSA group in both living donor kidney transplantation and deceased donor kidney transplantation.

*Conclusions: Low dose HLA-DSA is associated with increased acute antibody mediated rejection in living donor kidney transplantation. In low dose HLA-DSA, HLA-DSA class II rather than HLA-DSA class I is considered to play an important role in increased acute antibody mediated rejection. However, the impact of low dose HLA-DSA is unclear in deceased donor kidney transplantation.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Kim S, Lee S, Ko E, Ban T, Min J, Yoon H, Yang C, Chung B. Impact of Low Dose Donor Specific Anti-HLA Antibodies between Living Donor versus Deceased Donor Kidney Transplantation [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/impact-of-low-dose-donor-specific-anti-hla-antibodies-between-living-donor-versus-deceased-donor-kidney-transplantation/. Accessed May 11, 2025.

« Back to 2020 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences